euro adhoc: Intercell AG / other / European Patent granted for Intercell’s synthetic adjuvant IC31TM

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc.
The issuer is responsible for the content of this announcement.
--------------------------------------------------------------------------------

26.04.2006

Intercell (VSE, "ICLL") announced today that the European Patent
Office has granted an additional key patent covering a component of
Intercell’s novel proprietary synthetic adjuvant IC31TM. The newly
issued patent (EP 1 326 634 B) specifically covers the peptide (KLK)
component of IC31TM. A separate patent (EP 1 296 713 B), which was
issued in 2003, covers the second component of the adjuvant, an
oligonucleotide (I-ODN). Both patents together provide broad patent
protection for the use of IC31TM as a B- and T-cell adjuvant in
vaccines.

"With the issuance of this patent, we have succeeded in establishing
solid patent coverage for our innovative adjuvant, IC31TM", states
Alexander von Gabain, Chief Scientific Officer of Intercell. "The
market demand for novel adjuvants which are safe and potent is
growing. We are convinced that IC31TM will play a key role in our
future vaccine development programs and those of our strategic
partners, which include major players in the vaccine industry."

About IC31TM

IC31TM is an adjuvant that induces T-cell and B-cell responses by
using a unique synthetic formulation which combines the
immunostimulating properties of an anti-microbial peptide, KLK, and
an immunostimulatory oligodeoxynucleotide, ODN1a. The two component
solution can be simply mixed with antigens; no conjugation is
required.

Intercell currently uses IC31™ in collaborations with a number of
global vaccine companies and biotech companies. These collaborations
include the development of a tuberculosis vaccine in Phase I clinical
trials, which has been partnered with the Danish Statens Serum
Institut, and the development of a therapeutic Hepatitis B vaccine
with SciGen Ltd.

end of announcement euro adhoc 26.04.2006 07:30:00
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market